Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Toripalimab (Loqtorzi)

decorative image of the issue cover

Published April 16, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses toripalimab (Loqtorzi), 240 mg/6 mL (40 mg/mL) solution for IV infusion.
  • Indication: as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.